Navigation Links
Novavax Reports First Quarter 2009 Financial Results
Date:5/8/2009

r of this year.
  • Improved the balance sheet by retiring $17.0 million out of the total $22.0 million principle amount of outstanding convertible notes. These notes carried a coupon rate of 4.75% payable semi-annually and had a maturity date of July 15, 2009. Under the terms of the early retirement, Novavax paid 70% of the principal plus accrued and unpaid interest, or $12.1 million, in cash and issued 2,040,000 shares of its common stock for the remaining 30% of the principal, valued in the transaction as approximately $5.1 million. The remaining $5.0 million in outstanding convertible notes will be due on July 15, 2009 and can be paid up to 50% in stock at maturity at Novavax's option.
  • Increased liquidity by raising $11.0 million from sale of 12.5 million shares of common stock to a wholly owned subsidiary of Cadila Pharmaceuticals and raising approximately $7.5 million from the sale of approximately 3.1 million shares of common stock under the sales agreement with Wm Smith & Co.

  • "We are pleased with the significant clinical, corporate, and financial progress we have made in the past few months," said Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer. "We have made substantial progress in advancing our VLP based influenza vaccines over the past three years. The recent emergence of the novel influenza A (H1N1) virus highlights the potential value of our recombinant VLP technology as we can produce a genetically matched vaccine to the outbreak strain in about half the time of traditional vaccine technologies. We are in communication with governments and health authorities around the world and will help in any way possible. With the improvement in our financial position, we are in a much stronger position to continue development of our vaccine pipeline and pursue partnerships."

    The anticipated milestones for the remainder of 2009 include:

    <
    '/>"/>
    SOURCE Novavax, Inc.
    Copyright©2009 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
    2. Novavax Announces Release Date of 2009 First Quarter, Financial Results and Investor Conference Call
    3. Novavax Announces Early Retirement of $17 Million of Convertible Debt
    4. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
    5. Novavax Announces New Capital Infusion Through a Strategic Alliance with Cadila Pharmaceuticals of India
    6. Novavax Announces New Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    7. Novavax Announces Release Date of 2008 Fourth Quarter Financial Results and Investor Conference Call
    8. Novavax to Present at Cowen and Company 29th Annual Healthcare Conference
    9. NOVAVAX Announces Preclinical Study Results for a Respiratory Syncytial Virus (RSV) Vaccine Candidate Directed Against the Fusion (F) Protein
    10. Novavax and Vivalis Sign a Research License Agreement to Use the EB66(R) Cell Line for the Production of Virus Like Particle Based Vaccines
    11. Novavax Announces Operational Status of Its Vaccine Pilot Plant and Commercial Launch Facility
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:5/4/2015)... FRANCISCO, Calif. , May 4, 2015 /PRNewswire/ ... biopharmaceutical company focused on the development and commercialization ... announced today the completion of its merger with ... In conjunction with the closing of the merger, ... a combination of new investors and all current ...
    (Date:5/4/2015)... BOSTON , May 4, 2015 ... development of novel therapies for neurological and neuropsychiatric ... has initiated dosing of Alzheimer,s patients in a ... candidate, GC021109, a compound developed as a potential ... disease is innovative in that it both promotes ...
    (Date:5/4/2015)... May 4, 2015 /PRNewswire/ - Fluorinov Pharma (Fluorinov), ... the appointment of Dr. Roger J Garceau, to ... biotech companies in matters including corporate development and ... and adds significant regulatory expertise as Fluorinov transitions ... brings 30 years of pharmaceutical development experience to ...
    (Date:5/4/2015)... Genedata, a leading provider of advanced ... research, today announced the release of Genedata ... enterprise solution for biologics R&D. This first-in-class workflow ... and development of novel biotherapeutics. Version 5.0 enables ... optimization and developability requirements. Genedata will present highlights ...
    Breaking Biology Technology:Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 2Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 3Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 4Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 5Tobira Therapeutics Completes Financing and Merger with Regado Biosciences 6GliaCure Initiates Phase 1b Dosing in Alzheimer's Patients 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 2Roger J Garceau joins Fluorinov board, adds clinical expertise to bromodomain program and oncology pipeline 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 2Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 3Genedata Biologics 5.0 – Antibody Engineering and Developability Assessment Advances 4
    ... New Launches Should Contribute Significantly in Second Half, ... PRX ) today announced results for the,second quarter ended ... For the second quarter ended June 28, 2008, Par ... $20.1 million, or $0.60 per diluted,share. This is compared with ...
    ... ITMN ) today announced that Daniel G. Welch, ... Canaccord Adams 28th Annual,Global Growth Conference in Boston on ... access a live audio webcast of the presentation, investors ... relations page of InterMune,s,corporate website at http://www.intermune.com . ...
    ... YORK, Aug. 7 Microbes, Inc. today announced that ... all of its outstanding,Class B Common Stock Purchase Warrants, ... 2 until 12:00 midnight, New York City time, on,Friday, ... at 12:00,midnight, New York City time, on August 7, ...
    Cached Biology Technology:Par Pharmaceutical Reports Second Quarter 2008 Results 2Par Pharmaceutical Reports Second Quarter 2008 Results 3Par Pharmaceutical Reports Second Quarter 2008 Results 4Par Pharmaceutical Reports Second Quarter 2008 Results 5Par Pharmaceutical Reports Second Quarter 2008 Results 6Par Pharmaceutical Reports Second Quarter 2008 Results 7Par Pharmaceutical Reports Second Quarter 2008 Results 8
    (Date:3/31/2015)... NEW YORK , March 31, 2015  Elephant ... the "Company"), a global provider of Software Defined Network ... solutions, today announced total revenue of approximately $20.4 million ... to a restated $19.5 million for the year ended ... of calendar 2014, the Company had completed its multi-year ...
    (Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
    (Date:3/24/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/hdgz7h/global_iris ) has ... Market 2015-2019" report to their offering. ... grow at a CAGR of 23.5 percent over the ... scenario and the growth prospects of the Global Iris ... market size, the report considers the revenue generated from ...
    Breaking Biology News(10 mins):Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2
    ... a key source of water for millions of people in ... climate changes as expected and future water usage is not ... of Oceanography, UC San Diego. Without Lake ... no buffer to sustain the population of the Southwest through ...
    ... Feb. 11 Most fashion consumers consider,custom-made jeans ... lottery,winners. But Intellifit, a leader in proprietary apparel ... perception., This week, the company will begin ... company retail store outside of Philadelphia. Using Intellifit,technology, ...
    ... the Moores Cancer Center at University of California, San Diego ... were treated with a gene therapy protocol began making antibodies ... be published on line the week of February 11-15 in ... of Science. Researchers led by Thomas J. Kipps, M.D., ...
    Cached Biology News:Lake Mead could be dry by 2021 2Lake Mead could be dry by 2021 3Intellifit(R) Offers Custom-Made Jeans with a High-Tech Twist 2Gene therapy protocol at UCSD activates immune system in patients with leukemia 2